Sermorelin Price: What the 11.31 mg Line Changes

Sermorelin price is quoted three ways on the same listing, and none of the three is the number you actually want. $99.99 is a list. $72.00 is what the site charges. $36.00 is what the code makes it. All are prices per vial, and a vial is not a unit of anything.

A per-milligram figure is the useful form, and it requires a denominator. On this compound the denominator is unusual: the certificate for the linked lot reports a measured quantity rather than restating the label, so both the assumed and the measured version of the arithmetic can be run and compared.

Sermorelin price at two denominators

The left column divides by the 10 mg printed on the label. The right divides by the 11.31 mg that MZ Biolabs reported for lot 38-01260229 on 7 February 2026. Every figure below is arithmetic on published numbers.

The correction moves every row by the same 13.1 percent, which is the useful property: it does not change the ordering, so it cannot be used to make one price point look better than another. What it changes is a comparison against a seller who publishes no quantity result at all, because that seller’s figure lives in the middle column and has never been checked.

Why the measured denominator has a fence around it

11.31 mg is what one laboratory reported for one lot on one date. It is not a specification, not a tolerance, and not a claim about the next vial. Excess fill above a labelled quantity is a normal and deliberate feature of regulated injectable manufacturing, where it is controlled and documented; this is not a regulated product, and the figure carries none of that framework with it.

Treating it as a standing property would produce exactly the error this page exists to avoid. A reader who assumes 13.1 percent of free material on every future order is budgeting against a number nobody promised. The correct use of the figure is narrow: it tells you that this vendor publishes a quantity result at all, which is itself informative, and it lets you recompute one batch’s cost basis rather than accept a label.

It is also worth knowing what the same certificate does not report. There is no bacterial endotoxin result on it and no sterility screen, so the document that improves the denominator says nothing about the microbiological question. A cheaper milligram of material with a narrower test scope is not obviously a better purchase, which is the reasoning behind our scored source comparison.

What the tiers and the carriage threshold actually do

Two published mechanics sit alongside the code. Quantity tiers take 3, 5 or 10 percent off the list price at three, five and ten units. Free carriage begins at $250. Both are straightforward in isolation and ambiguous together.

The ambiguity is worth naming rather than papering over. Whether a tier percentage applies on top of a code discount is not documented anywhere we can cite. Nor is whether the $250 carriage threshold is measured against the subtotal before a discount or the total after it, and the two readings qualify different baskets: three vials at list come to $299.97 and clear the threshold on the first reading, while seven discounted vials at $36.00 come to $252.00 and clear it on the second. A basket built on the wrong assumption arrives with a shipping line on it.

There is a second reason to build the basket deliberately rather than by unit price. One vial is one lot, and one lot is one certificate. Three vials bought together may ship from the same lot, in which case a single document covers all of them and a single handling problem affects all of them. Three vials bought across separate orders are more likely to carry separate lot numbers, which means separate certificates to read and independent material to work from. Neither arrangement is cheaper; they answer different questions, and the per-milligram column does not distinguish them.

The practical rule is that the cart is the only authority. Everything upstream of it is a published rule, and published rules in this market are frequently narrower than they read. How to confirm a code has applied before paying, and what a very large headline discount usually says about the list price it is taken from, is the subject of our discount analysis.

The comparison the arithmetic cannot make

The question readers arrive with is usually whether $36.00 is cheaper than a clinic. It is, and the comparison is meaningless, because the two transactions differ in kind rather than in price.

Sermorelin is unusual among the compounds sold this way in that both sides of that comparison exist. It was an approved drug, sold as Geref by EMD Serono under NDA 019863 for pituitary diagnostics and NDA 020443 for therapeutic use, the latter approved 26 September 1997. Both applications are discontinued and no current US label exists. FDA’s record carries the determination that they were not removed from sale for reasons of safety or effectiveness, and sermorelin is absent from FDA’s Category 2 list of bulk substances flagged as posing significant safety risks in compounding. A pharmacy filling a prescription therefore has a route that most research peptides do not offer.

What that route costs is not published in any form we can verify. Prescription and programme pricing is set per prescriber and per pharmacy, frequently bundled with consultation and laboratory work, and quoted monthly rather than per milligram. We are not going to estimate it. A fabricated comparison figure would be worse than an honest gap, and the honest summary is that one purchase buys characterised material with no clinical oversight while the other buys oversight with no analytics you get to read. The route itself is set out in our prescription guide.

What no price point buys

Evidence for the use the market is selling. The approved indications were paediatric growth hormone deficiency and pituitary diagnostics, and that is where the literature sits: PubMed returns 332 papers mentioning sermorelin, three with it in the title, and nothing at all for the anti-aging framing. ClinicalTrials.gov registers no studies naming it as an intervention.

The registry search is worth running once for the shape of the result. Dozens of studies come back and none of them name this compound; they are growth hormone-releasing hormone, tesamorelin and octreotide trials surfaced by synonym matching. Sermorelin is GHRH(1-29), so some of that work is genuinely relevant, and a trial of a different molecule is still a trial of a different molecule. A page that prices this compound against clinical evidence is pricing something it has not got. What the vial does contain, confirmed against sequence and mass, is covered in our identity guide.